Phase II Study of Neoadjuvant Gemcitabine, Nab-paclitaxel, Durvalumab (MEDI4736) (Anti-PD-L1), and Oleclumab (Anti-CD73) in the Treatment of Resectable/Borderline Resectable Primary Pancreatic Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04940286

Title field or adapter rule

{'original_value': 'Phase II Study of Neoadjuvant Gemcitabine, Nab-paclitaxel, Durvalumab (MEDI4736) (Anti-PD-L1), and Oleclumab (Anti-CD73) in the Treatment of Resectable/Borderline Resectable Primary Pancreatic Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:23.887620+00:00

Published At

2026-10-07T00:00:00+00:00

Record Updated At

2026-10-07

Source Retrieved At

2026-10-31T22:17:54.613222+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Borderline Resectable Pancreatic Adenocarcinoma", "Resectable Pancreatic Adenocarcinoma", "Stage IA Pancreatic Cancer AJCC v8", "Stage IB Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-07", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT04940286"

protocolSection.identificationModule.officialTitle

"Phase II Study of Neoadjuvant Gemcitabine, Nab-paclitaxel, Durvalumab (MEDI4736) (Anti-PD-L1), and Oleclumab (Anti-CD73) in the Treatment of Resectable/Borderline Resectable Primary Pancreatic Adenocarcinoma"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Borderline Resectable Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Resectable Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Stage IA Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IB Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IIA Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IIB Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Treatment (durvalumab, oleclumab, nab-paclitaxel, gemcitabine)'], 'description': 'Given IV', 'name': 'Durvalumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (durvalumab, oleclumab, nab-paclitaxel, gemcitabine)'], 'description': 'Given IV', 'name': 'Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (durvalumab, oleclumab, nab-paclitaxel, gemcitabine)'], 'description': 'Given IV', 'name': 'Nab-paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (durvalumab, oleclumab, nab-paclitaxel, gemcitabine)'], 'description': 'Given IV', 'name': 'Oleclumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Gemcitabine (protocolSection.armsInterventionsModule.interventions[].name)
• Nab-paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.